Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07019259
- Status
- Recruiting
Conditions
- Cancer
- Chemotherapy-induced Peripheral Neuropathy
- Childhood Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Anodyne Therapy System — DEVICESurvivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.
Study Details
The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.
Key Dates
- Start date
- Jun 30, 2025
- Status verified
- Jul 2025
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Light TherapyWeek 1 will include a baseline evaluation in clinic. In weeks 1-6, participants will complete 18 total light therapy sessions (3 sessions/week, 15/minutes session). The first session will be observed in clinic at the time of the baseline evaluation, and the remaining 17 sessions will be completed at home. In Week 7 survivors will follow-up in clinic for a repeat evaluation with the physical therapist (or study team member). .
Primary Outcome Measure
Feasibility of light therapy protocol [ Time Frame: 7 weeks ]
Central Contacts
- Rozalyn Rodwin, MD203-785-2407
- Jaime Rotatori, BSN, MS203-785-2407
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale New Haven Health Smilow York Street Hospital | New Haven | Connecticut | 06520 | - |
| Yale New Haven Health Park Avenue Medical Center | Trumbull | Connecticut | 06611 | - |
Find similar trials in New Haven, CT
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Pan Tumor Rollover StudyPHASE2 · Recruiting · Bristol-Myers Squibb · Huntsville, Alabama
- TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPHASE1 · Recruiting · Tizona Therapeutics, Inc · Tucson, Arizona
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067PHASE1/PHASE2 · Recruiting · Simcha IL-18, Inc. · Scottsdale, Arizona